A Phase 2 interventional study of Tolvaptan MR and Tolvaptan MR in Autosomal Dominant Polycystic Kidney Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-06-14.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 13th largest by enrollment, is one of 4 that started in 2010, is one of 7 in phase 2, and was the 5th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2010.
This study's enrollment of 25 is below the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 91 across the 18 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 16 finished, 13 (81%) have results posted.
Among the 17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd., this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2010, is one of 5 in phase 2, and was the 5th registered.
Otsuka Holdings Co., Ltd.’s Polycystic Kidney, Autosomal Dominant studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Polycystic Kidney, Autosomal Dominant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To establish pharmacokinetics (PK), pharmacodynamics (PD), and adverse event (AE) profile of tolvaptan administered as the modified-release (MR) formulation in ADPKD subjects. The goals of this trial are two-fold:
Group 1 will have 12 subjects enrolled in a 3-period, randomized, crossover to compare multiple doses of a 90-30 mg split-dose of the tolvaptan IR formulation, a 120 mg once daily (QD) dose of the tolvaptan MR formulation, and, in an incomplete block randomization, multiple doses of either 20 mg QD, 60 mg QD, or 20 mg twice daily (BID) tolvaptan MR formulation. All dose regimens will be administered for 7 days. Placebo doses will be administered in order to mask QD vs BID treatments.
Group 2 will have 12 subjects enrolled in a 3-period, randomized, crossover to compare multiple oral doses of the tolvaptan MR formulation administered for 7 days as 20 mg QD, 60 mg QD, and 20 mg BID. Placebo capsules will be administered in order to mask QD vs BID treatments.
Subjects will have in-clinic assessments on 12 days to obtain 24-hour PK and PD data. Subjects will visit the clinic from the afternoon of Day -1 through the morning of Day 1. They will return at the end of each dosing period for a similar inpatient period (ie, from the afternoon of Day 6 through the morning of Day 8, from the afternoon of Day 13 through the morning of Day 15, from the afternoon of Day 20 through the morning of Day 22). Except for the first dose of each period and the doses taken in the clinic on the last day of each regimen and the afternoon of Days 6, 13 and 20, all other doses will be taken by the subject as an outpatient.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tolvaptan MR
Drug: Tolvaptan MR
Drug: Tolvaptan MR
Drug: Tolvaptan MR
Drug: Tolvaptan IR
20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
Also known as: OPC-41061
20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
Also known as: OPC-41061
60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
Also known as: OPC-41061
90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
Also known as: OPC-41061
120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
Also known as: OPC-41061
Maximum (Peak) Plasma Concentration of the Drug [Cmax] and Minimum (Trough) Plasma Concentration of the Drug [Cmin] After Tolvaptan Treatment on Day 7.
Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Maximum and minimum plasma concentration of the drug was calculated.
Time frame: Day 7
Time to Maximum (Peak) Plasma Concentration (Tmax) After Tolvaptan Treatment on Day 7.
Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Time to maximum plasma concentration was calculated.
Time frame: Day 7
Area Under the Concentration-time Curve During the Dosing Interval at Steady State and Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUCT & AUC0-24h) After Tolvaptan Treatment on Day 7.
Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Hence, both AUCT and AUC0-24h values were calculated.
Time frame: Day 7
Number of Participants With Urine Osmolality < 300 mOsm/kg at 23.5 Hours Postdose.
For determination of duration of urine osmolality \<300 mOsm/kg, the value was the end time of the last collection interval in which urine osmolality was \<300 mOsm/kg. Day 8 in the table below was defined as Day 8 of Period 1, Day 15 of Period 2, and Day 22 of period 3.
Time frame: 23.5 hours post-dose
Change From Baseline in Urine Osmolality Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24h) at Day 7.
The AUC0-24h for urine osmolality was determined by multiplying the concentration by the collection interval duration for each collection interval and summing all the intervals in the 24-hour period. If the urine volume for an interval is zero, the duration of that interval will be added to the next collection interval. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.
Time frame: Day 7
Change From Baseline in Urine Osmolality at Day 7.
To determine the tolerability and nighttime urinary suppression of osmolality. The urine osmolality was summarized by collection interval (0 to 4, 4 to 8, 8 to 12, 12 to 16, and 16 to 24 hours)
Time frame: 0-4, 4-8, 8-12, 12-16, 16-24 Hours at Day 7
Change From Baseline in Urine Volume at 24 Hours at Day 7.
Urine volume was collected by 0 to 24-hour interval at Day 7. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.
Time frame: Day 7
Change From Baseline in Urine Volume by Interval at Day 7.
Urine volume collected was by interval (0-4, 4-8, 8-12, 12-16, 16-24 hours). Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.
Time frame: 0-4, 4-8, 8-12, 12-16, 16-24 Hours at Day 7
Duration of Urine Osmolality Less Than 300 mOsm/kg at Baseline and Day 7.
Duration of urine osmolality remains below 300 mOsm/kg was the sum of the durations (nominal times) of all intervals where the urine concentration was \< 300 mOsm/kg. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2, and Day 21 of Period 3.
Time frame: Baseline and Day 7
Change From Baseline in Number of Urine Voids During Awake Periods.
Average number of daily urine voids during awake periods for each dose group. Day 1 was defined as Day1 of Period 1, Day 8 of Period 2 adn Day 15 of Period 3; Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3; Same rule applied to Day 2 and Day 6.
Time frame: Days 1, 2, 3, 4, 5, 6 and 7
Change From Baseline in Number of Urine Voids During Sleep Periods.
Average number of daily urine voids during sleep periods for each dose group. Day 1 was defined as Day 1 of Period 1, Day 8 of Period 2, Day 15 of Period 3; Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3; Same rule applied to Day 2 to 6.
Time frame: Days 1, 2, 3, 4, 5, 6 and 7
Change From Baseline in Symptom Burden by Autosomal Dominant Polycystic Kidney Disease (ADPKD) Nocturia Quality of Life Questionnaire at Day 6.
In ADPKD Nocturia Quality of Life Questionnaire, questions 1 to 11 (with possible scores ranging from 0 to 4 and higher scores indicating better quality of life) were pooled to provide a total score (maximum of 44 points). Response scores of Question 12 (with possible scores ranging from 1 to 10, with higher scores indicating more interference (worse quality of life) with everyday life due to urination at night) were pooled separately. Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.
Time frame: Day 6
Number of Participants Experiencing Urinary Urgency Based on Urinary Urgency Questionnaire (Question 1) at Baseline and Day 6.
For the ADPKD Urinary Urgency Questionnaire, Question 1 (currently experiencing urgency?) was assigned 'Yes' or 'No' to measure current urine urgency status. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.
Time frame: Baseline and Day 6
Change From Baseline in Urinary Urgency Questionnaire (Questions 2 to 5 and Questions 7 to 14) at Day 6.
Question 2 to Question 6 were assigned scores of 0 to 4 with higher scores indicating worse cases in experience of urinary urgency. Scores for Question 2 to Question 5 were pooled, with a maximum possible score of 16. Question 6 was excluded from the analysis since it was only asked at screening. Question 7 to Question 14 were also assigned scores of 0 to 4 with higher scores indicating worse cases in impact of urinary urgency on life; scores for these questions were pooled, with a maximum possible score of 32. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.
Time frame: Day 6
Number of Participants Experiencing Urinary Frequency Based on Urinary Frequency Questionnaire (Question 1) at Baseline and Day 6.
The ADPKD Urinary Frequency Questionnaire: Question 1 (currently experiencing frequency) was assigned 'Yes' or 'No' to measure current urine frequency status. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.
Time frame: Baseline and Day 6
Change From Baseline in Urinary Frequency Questionnaire (Question 2 and Questions 3 to 10) at Day 6.
Question 2 asked, "During the last 5 days, how much has urinary frequency bothered you?" In order to score the response, the written answers were assigned values from 0 to 4 as follows: 0) Not at all, 1) Somewhat, 2) Moderately, 3) Quite a bit, and 4) Constantly. Question 3 to Question 10 were assigned scores of 0 to 4 with higher scores indicating worse cases in impact of urinary frequency on life; scores for these questions were pooled, with a maximum possible score of 32. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.
Time frame: Day 6
Ranking of Treatment Tolerability.
Ranking of treatment tolerability was evaluated based on a questionnaire. At Day 22, participants were asked the following questions and their responses recorded on the eCRF: "Which treatment period did you find most tolerable?" and "Which treatment period did you find the least tolerable?".
Time frame: Day 22/Early Termination
Study was conducted at 6 centers in the United States. 25 participants were randomized (12+13) to Group 1 \& 2 with 5 \& 3 treatment sequences, respectively; received tolvaptan Modified-release \[MR\] capsules \& Immediate-release \[IR\] tablets in Group 1 \& MR in Group 2 over 3 therapy periods (each 7 days) in parallel-group, crossover design
| Milestone | Group 1: DAE | Group 1: DBE | Group 1: DCE | Group 1: EAD | Group 1: EBD | Group 1: ECD | Group 2: FGH | Group 2: HFG | Group 2: GHF |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 5 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Group 1: DAE | Group 1: DBE | Group 1: DCE | Group 1: EAD | Group 1: EBD | Group 1: ECD | Group 2: FGH | Group 2: HFG | Group 2: GHF |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 5 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Group 1: DAE | Group 1: DBE | Group 1: DCE | Group 1: EAD | Group 1: EBD | Group 1: ECD | Group 2: FGH | Group 2: HFG | Group 2: GHF |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 5 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Maximum and minimum plasma concentration of the drug was calculated.
| ng/mL | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Cmax | 140 ± 68.4 | 175 ± 60.1 | 350 ± 156 | 669 ± 370 | 716 ± 344 |
| Cmin | 14.7 ± 9.95 | 50.8 ± 24.0 | 51.1 ± 32.3 | 139 ± 75.5 | 57.5 ± 41.8 |
Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Time to maximum plasma concentration was calculated.
| Hours | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Time to Maximum (Peak) Plasma Concentration (Tmax) After Tolvaptan Treatment on Day 7. | 6.00 (3.97 to 10.00) | 6.00 (3.97 to 16.00) | 6.00 (3.98 to 9.00) | 5.98 (3.97 to 6.00) | 2.00 (1.00 to 9.00) |
Blood samples (6 mL) for determination of tolvaptan PK parameters were collected on Day 1 predose, and on Days 7, 14 and 21 at predose, and 1, 2, 4, 6, 8, 9, 10, 12, 16, and 24 hours postdose. If a sample was not drawn at the designated time, a window of ± 3 minutes for each blood draw was acceptable. Hence, both AUCT and AUC0-24h values were calculated.
| ng·h/mL | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Area Under the Concentration-time Curve During the Dosing Interval at Steady State and Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUCT & AUC0-24h) After Tolvaptan Treatment on Day 7. | 1260 ± 654 | 2310 ± 704 | 3600 ± 1670 | 7740 ± 3650 | 6570 ± 3230 |
For determination of duration of urine osmolality \<300 mOsm/kg, the value was the end time of the last collection interval in which urine osmolality was \<300 mOsm/kg. Day 8 in the table below was defined as Day 8 of Period 1, Day 15 of Period 2, and Day 22 of period 3.
| Participants | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Baseline | 1 | 1 | 1 | 0 | 0 |
| Day 8 | 5 | 11 | 9 | 11 | 11 |
The AUC0-24h for urine osmolality was determined by multiplying the concentration by the collection interval duration for each collection interval and summing all the intervals in the 24-hour period. If the urine volume for an interval is zero, the duration of that interval will be added to the next collection interval. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.
| mOsm/kg*Hour | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Urine Osmolality Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24h) at Day 7. | -2546 ± 1743 | -3438 ± 2277 | -4209 ± 2569 | -4325 ± 2237 | -4620 ± 2419 |
To determine the tolerability and nighttime urinary suppression of osmolality. The urine osmolality was summarized by collection interval (0 to 4, 4 to 8, 8 to 12, 12 to 16, and 16 to 24 hours)
| mOsm/kg | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| 0-4 Hour | 2.6 ± 132.1 | -0.7 ± 111.9 | -88.9 ± 130.9 | -59.5 ± 169.2 | -123.3 ± 139.5 |
| 4-8 Hour | -140.9 ± 127.1 | -128.3 ± 127.2 | -188.2 ± 140.5 | -186.1 ± 161.1 | -191.8 ± 155.1 |
| 8-12 Hour | -123.1 ± 115.9 | -172.1 ± 129.8 | -201.8 ± 158.8 | -167.1 ± 148.7 | -166.9 ± 131.7 |
| 12-16 Hour | -128.3 ± 142.9 | -193.6 ± 152.5 | -195.8 ± 151.6 | -176.3 ± 121.8 | -178.3 ± 128.9 |
| 16-24 Hour | -123.4 ± 102.6 | -182.4 ± 145.6 | -188.8 ± 160.0 | -246.1 ± 108.9 | -239.8 ± 117.8 |
Urine volume was collected by 0 to 24-hour interval at Day 7. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.
| mL | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Urine Volume at 24 Hours at Day 7. | 1111 ± 919 | 2066 ± 1237 | 2396 ± 1022 | 3722 ± 1776 | 3820 ± 1759 |
Urine volume collected was by interval (0-4, 4-8, 8-12, 12-16, 16-24 hours). Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3.
| mL | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| 0-4 Hour | -87 ± 348 | -118 ± 391 | 56 ± 345 | 87 ± 449 | 241 ± 412 |
| 4-8 Hour | 326 ± 531 | 423 ± 439 | 636 ± 382 | 785 ± 605 | 825 ± 472 |
| 8-12 Hour | 301 ± 317 | 529 ± 349 | 689 ± 603 | 887 ± 558 | 801 ± 494 |
| 12-16 Hour | 314 ± 328 | 635 ± 473 | 667 ± 337 | 926 ± 459 | 910 ± 738 |
| 16-24 Hour | 257 ± 407 | 598 ± 482 | 286 ± 421 | 1038 ± 642 | 1044 ± 421 |
Duration of urine osmolality remains below 300 mOsm/kg was the sum of the durations (nominal times) of all intervals where the urine concentration was \< 300 mOsm/kg. Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2, and Day 21 of Period 3.
| Hours | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Baseline | 8.0 (0 to 24.0) | 8.0 (0 to 24.0) | 8.0 (0 to 24.0) | 14.0 (0 to 24.0) | 14.0 (0 to 24.0) |
| Day 7 | 16.0 (4.0 to 24.0) | 24.0 (4.0 to 24.0) | 24.0 (8.0 to 24.0) | 24.0 (20.0 to 24.0) | 24.0 (24.0 to 24.0) |
Average number of daily urine voids during awake periods for each dose group. Day 1 was defined as Day1 of Period 1, Day 8 of Period 2 adn Day 15 of Period 3; Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3; Same rule applied to Day 2 and Day 6.
| Number of urine voids | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Day 1 | 1.7 ± 4.1 | 1.5 ± 3.1 | 3.5 ± 4.3 | 5.6 ± 5.6 | 4.8 ± 4.1 |
| Day 2 | -0.4 ± 2.9 | 1.2 ± 4.0 | 1.8 ± 4.1 | 4.8 ± 7.8 | 3.8 ± 4.2 |
| Day 3 | -0.8 ± 2.4 | 0.9 ± 2.4 | 2.4 ± 3.9 | 3.1 ± 4.6 | 3.3 ± 5.2 |
| Day 4 | -1.4 ± 2.3 | 1.5 ± 3.8 | 0.4 ± 5.0 | 2.8 ± 5.0 | 3.7 ± 5.9 |
| Day 5 | -0.5 ± 2.9 | 0.6 ± 3.5 | -0.4 ± 4.2 | 3.3 ± 5.6 | 4.0 ± 4.9 |
| Day 6 | 0.0 ± 3.3 | 2.9 ± 4.1 | 5.8 ± 10.6 | 2.3 ± 6.8 | 4.8 ± 5.2 |
| Day 7 | 2.0 ± 3.0 | 3.5 ± 2.4 | 3.5 ± 3.8 | 2.8 ± 6.4 | 4.3 ± 4.5 |
Average number of daily urine voids during sleep periods for each dose group. Day 1 was defined as Day 1 of Period 1, Day 8 of Period 2, Day 15 of Period 3; Day 7 was defined as Day 7 of Period 1, Day 14 of Period 2 and Day 21 of Period 3; Same rule applied to Day 2 to 6.
| Number of urine voids | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Day 1 | 0.6 ± 1.6 | 1.1 ± 2.0 | 0.4 ± 2.2 | 2.5 ± 1.7 | 1.5 ± 1.6 |
| Day 2 | -0.2 ± 1.7 | 0.8 ± 1.6 | 0.8 ± 1.9 | 1.8 ± 1.4 | 1.7 ± 1.2 |
| Day 3 | 0.1 ± 1.0 | 1.4 ± 2.4 | 0.8 ± 1.7 | 1.9 ± 1.5 | 1.9 ± 1.7 |
| Day 4 | 0.6 ± 2.3 | 0.7 ± 1.6 | 0.5 ± 1.7 | 1.7 ± 1.3 | 1.8 ± 1.9 |
| Day 5 | 0.3 ± 1.3 | 0.9 ± 2.0 | 0.2 ± 1.4 | 1.0 ± 2.0 | 0.9 ± 1.7 |
| Day 6 | 1.2 ± 3.3 | 1.3 ± 2.0 | 0.4 ± 1.6 | 1.1 ± 2.1 | 1.7 ± 1.7 |
| Day 7 | 0.1 ± 1.3 | 1.0 ± 1.7 | 0.9 ± 1.8 | 1.8 ± 2.4 | 2.1 ± 1.9 |
In ADPKD Nocturia Quality of Life Questionnaire, questions 1 to 11 (with possible scores ranging from 0 to 4 and higher scores indicating better quality of life) were pooled to provide a total score (maximum of 44 points). Response scores of Question 12 (with possible scores ranging from 1 to 10, with higher scores indicating more interference (worse quality of life) with everyday life due to urination at night) were pooled separately. Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.
| Units on a scale | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Nocturia Quality of life Question (Q) 1 To Q 11 | -1.5 ± 4.3 | -6.9 ± 9.9 | -5.1 ± 7.6 | -15.0 ± 13.3 | -13.1 ± 12.3 |
| Nocturia Quality of life Q 12 | 0.6 ± 1.3 | 1.9 ± 2.7 | 1.4 ± 2.5 | 4.2 ± 3.6 | 3.7 ± 3.5 |
For the ADPKD Urinary Urgency Questionnaire, Question 1 (currently experiencing urgency?) was assigned 'Yes' or 'No' to measure current urine urgency status. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.
| Participants | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Baseline | 5 | 3 | 3 | 2 | 2 |
| Day 6 | 8 | 13 | 12 | 10 | 11 |
Question 2 to Question 6 were assigned scores of 0 to 4 with higher scores indicating worse cases in experience of urinary urgency. Scores for Question 2 to Question 5 were pooled, with a maximum possible score of 16. Question 6 was excluded from the analysis since it was only asked at screening. Question 7 to Question 14 were also assigned scores of 0 to 4 with higher scores indicating worse cases in impact of urinary urgency on life; scores for these questions were pooled, with a maximum possible score of 32. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.
| Units on a scale | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Urinary urgency questionnaire-Question (Q) 2 to Q5 | 1.4 ± 2.1 | 3.2 ± 2.4 | 3.2 ± 3.1 | 4.6 ± 3.9 | 4.7 ± 3.0 |
| Urinary urgency questionnaire-Q 7 to Q 14 | 0.9 ± 1.2 | 4.2 ± 5.5 | 3.5 ± 5.0 | 10.9 ± 10.9 | 8.8 ± 9.8 |
The ADPKD Urinary Frequency Questionnaire: Question 1 (currently experiencing frequency) was assigned 'Yes' or 'No' to measure current urine frequency status. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.
| Participants | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Baseline | 5 | 4 | 4 | 4 | 4 |
| Day 6 | 10 | 15 | 16 | 12 | 12 |
Question 2 asked, "During the last 5 days, how much has urinary frequency bothered you?" In order to score the response, the written answers were assigned values from 0 to 4 as follows: 0) Not at all, 1) Somewhat, 2) Moderately, 3) Quite a bit, and 4) Constantly. Question 3 to Question 10 were assigned scores of 0 to 4 with higher scores indicating worse cases in impact of urinary frequency on life; scores for these questions were pooled, with a maximum possible score of 32. Baseline was defined as last pre-dose evaluation; Day 6 was defined as Day 6 of Period 1, Day 13 of Period 2 and Day 20 of Period 3.
| Units on a scale | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Urinary frequency questionnaire-Question (Q) 2 | 0.4 ± 0.6 | 1.1 ± 1.1 | 0.9 ± 0.9 | 1.7 ± 1.4 | 1.5 ± 1.1 |
| Urinary frequency questionnaire-Q 3 to Q 10 | 1.4 ± 2.1 | 4.6 ± 6.9 | 4.1 ± 5.7 | 12.2 ± 11.0 | 9.1 ± 10.5 |
Ranking of treatment tolerability was evaluated based on a questionnaire. At Day 22, participants were asked the following questions and their responses recorded on the eCRF: "Which treatment period did you find most tolerable?" and "Which treatment period did you find the least tolerable?".
| Participants | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| Most tolerable Group 1 | 3 | 2 | 3 | 1 | 1 |
| Most tolerable Group 2 | 10 | — | 3 | — | — |
| Least tolerable Group 1 | 0 | — | — | 4 | 6 |
| Least tolerable Group 2 | 0 | 7 | 6 | — | — |
Collected over Screening to seven days (+ 1 day) after the last dose of study medication.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MR 20 mg | — | 0/17 (0%) | 5/17 (29.4%) |
| MR 20+20 mg | — | 0/17 (0%) | 10/17 (58.8%) |
| MR 60 mg | — | 0/17 (0%) | 6/17 (35.3%) |
| MR 120 mg | — | 0/12 (0%) | 8/12 (66.7%) |
| IR 90+30 mg | — | 0/12 (0%) | 7/12 (58.3%) |
| Event | MR 20 mg | MR 20+20 mg | MR 60 mg | MR 120 mg | IR 90+30 mg |
|---|---|---|---|---|---|
| PolyuriaRenal and urinary disorders | 2/17 | 5/17 | 1/17 | 4/12 | 5/12 |
| PolydipsiaMetabolism and nutrition disorders | 1/17 | 2/17 | 0/17 | 2/12 | 3/12 |
| NocturiaRenal and urinary disorders | 1/17 | 2/17 | 1/17 | 1/12 | 3/12 |
| ThirstGeneral disorders | 1/17 | 3/17 | 2/17 | 2/12 | 1/12 |
| NauseaGastrointestinal disorders | 0/17 | 0/17 | 1/17 | 2/12 | 1/12 |
| PollakiuriaRenal and urinary disorders | 2/17 | 2/17 | 1/17 | 2/12 | 0/12 |
| HeadacheNervous system disorders | 0/17 | 2/17 | 1/17 | 1/12 | 0/12 |
| Micturition urgencyRenal and urinary disorders | 2/17 | 2/17 | 0/17 | 1/12 | 0/12 |
| Abdominal distensionGastrointestinal disorders | 0/17 | 0/17 | 0/17 | 0/12 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 0/17 | 0/17 | 0/17 | 1/12 | 0/12 |
| Age, Continuous(Years) | Group 1 | Group 2 | Total |
|---|---|---|---|
| Mean | 39.4 ± 4.3 | 36.8 ± 9.0 | 38.0 ± 7.1 |
| Sex: Female, Male(Participants) | Group 1 | Group 2 | Total |
|---|---|---|---|
| Female | 7 | 4 | 11 |
| Male | 5 | 9 | 14 |
The record gives a start of Oct 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2018, 7 years after primary completion. A results delay was requested in Feb 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Polycystic Kidney, Autosomal Dominant →
Otsuka Pharmaceutical Development & Commercialization, Inc. →